Summary of patients diagnosed with CML during pregnancy at Hammersmith Hospital, London
Characteristics (N = 11) . | Median (range); N [%] . |
---|---|
Age at diagnosis (years) | 33 (25-40) |
Trimester | |
1 | 6 [55] |
2 | 5 [45] |
CML phase | |
Chronic | 11 [100] |
WBC ( × 109/L) | 80 (14.7-215.4) |
Sokal score | |
Low | 6 [55] |
Intermediate | 2 [18] |
No data | 3 [27] |
Pregnancy outcome | |
Live birth | 10 [91] |
Miscarriage | 1 [9] |
Management in pregnancy | |
Observation | 3 [27] |
IFNa | 2 [18] |
Leukapheresis | 3 [27] |
IFN + leukapheresis | 3 [27] |
TKI started after pregnancy end | |
Imatinib | 8 (73) |
Dasatinib | 3 (27) |
Duration of TKI delay (months) | 7 (1-10) |
≥MR1 at 3 mo | 11 [100] |
≥CCyR at 6 mo | 9 [82] |
≥MMR at 12 mo | 8 [73] |
Characteristics (N = 11) . | Median (range); N [%] . |
---|---|
Age at diagnosis (years) | 33 (25-40) |
Trimester | |
1 | 6 [55] |
2 | 5 [45] |
CML phase | |
Chronic | 11 [100] |
WBC ( × 109/L) | 80 (14.7-215.4) |
Sokal score | |
Low | 6 [55] |
Intermediate | 2 [18] |
No data | 3 [27] |
Pregnancy outcome | |
Live birth | 10 [91] |
Miscarriage | 1 [9] |
Management in pregnancy | |
Observation | 3 [27] |
IFNa | 2 [18] |
Leukapheresis | 3 [27] |
IFN + leukapheresis | 3 [27] |
TKI started after pregnancy end | |
Imatinib | 8 (73) |
Dasatinib | 3 (27) |
Duration of TKI delay (months) | 7 (1-10) |
≥MR1 at 3 mo | 11 [100] |
≥CCyR at 6 mo | 9 [82] |
≥MMR at 12 mo | 8 [73] |
One patient was switched from IFN-α to PEG-IFN-α due to an adverse reaction to the drug.